BIND Biosciences, Inc.

BIND Biosciences, Inc. (BIND) is a biopharmaceutical company developing therapeutic targeted nanoparticles to significantly improve patients’ lives. The company was founded by two pioneers in the field: Dr. Robert Langer of MIT and Dr. Omid Farokhzad of Harvard Medical School.

Join Our Growing Team

BIND's collaborative culture provides a unique opportunity for talented and creative individuals to make a significant contribution in developing breakthrough targeted therapeutics. We are rapidly expanding to build a great company.

Our Technology

BIND's product platform leverages the convergence of polymeric biomaterials, nanoparticle engineering, and combinatorial synthesis to uniquely enable us to create optimally targeted nanoparticles for specific indications. These optimized nanoparticles concentrate drug at the site of disease while minimizing systemic exposure, thereby increasing efficacy and reducing side effects. Our initial product development efforts are in cardiovascular disease and cancer, though the platform has broad applicability across many therapeutic areas.

News at BIND Biosciences

• 04/15/2008
  BIND Biosciences, Inc. covered for second time in Wall Street Journal
• 12/19/2007
  BIND Biosciences, Inc. appoints Jim Wright, PhD as Chief Scientific Officer
• 11/27/2007
  BIND Biosciences, Inc. closes $16M Series B financing round
• 10/11/2007
  BIND Biosciences, Inc. receives $2M NIST ATP award
• 10/08/2007
  BIND Biosciences, Inc. awarded NIH Phase I SBIR Contract
• 09/12/2007
  BIND Biosciences, Inc. covered in Wall Street Journal